Clinical Trials Logo
  1. Home
  2. Acute Gout
  3. NCT00798369

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Acute Gout Clinical Trial

Official title:
An Adaptive Dose-ranging, Multi-center, Single-blind, Double-dummy, Active-controlled Trial to Determine the Target Dose of Canakinumab (ACZ885) in the Treatment of Acute Flares in Gout Patients Who Are Refractory or Contraindicated to NSAIDs and/or Colchicine

Clinical Trial Summary

This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the corticosteroid triamcinolone acetonide.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00798369
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date November 2008
Completion date August 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02674776 - Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout Phase 3
Not yet recruiting NCT05925166 - Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout N/A
Active, not recruiting NCT05328531 - Clinical Study of Genakumab for Injection in Patients With Acute Gout Phase 1/Phase 2
Completed NCT01080131 - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. Phase 3
Recruiting NCT05936268 - Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare Phase 2
Not yet recruiting NCT05936281 - Safety and Efficacy of Genakumab for Injection in Patients With Gout Initiating Urico-lowering Therapy Phase 2
Recruiting NCT05588908 - A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout Phase 1/Phase 2
Recruiting NCT05698680 - Prednisolone Versus Colchicine for Acute Gout in Primary Care Phase 4
Recruiting NCT05983445 - Safety & Efficacy of Genakumab in Patients With Frequent Flares Phase 3
Completed NCT00142558 - A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) Phase 4
Not yet recruiting NCT06169891 - A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout Phase 3
Completed NCT01029652 - Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study Phase 3
Withdrawn NCT00997581 - Apremilast Therapy for Acute Gouty Arthritis Phase 2